Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Prezista

    - PMLiVE

    Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

    An estimated 1.2 million people in the US are currently living with the virus

    - PMLiVE

    Gilead Sciences and Kymera enter oncology partnership worth up to $750m

    The companies will focus on advancing Kymera’s oral molecular glue degrader programme

    - PMLiVE

    Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

    More than 100 people in the US were diagnosed with HIV every day in 2023

    - PMLiVE

    Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC

    Primary biliary cholangitis affects approximately 163,000 people in Europe

    - PMLiVE

    Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults

    The company gained access to the drug through its $4.3bn acquisition of CymaBay

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    Gilead appoints Dietmar Berger as chief medical officer

    Berger most recently served as chief medical officer and global head of development at Sanofi

    - PMLiVE

    Cultivating Interest in Infectious Disease Education at ID Week 2024

    IDWeek starts tomorrow, October 16, and Medscape is bringing outcomes and education! We are excited to announce Medscape is presenting six posters that highlight the significant impact of our educational...

    Medscape Education

    - PMLiVE

    Gilead and AI-focused Genesis partner to develop small molecule therapies

    The companies will use Genesis’ AI platform to generate and optimise molecules for targets selected by Gilead

    - PMLiVE

    Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations

    “I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...

    Medscape Education

    - PMLiVE

    Gilead shares positive phase 3 results for twice-yearly HIV PrEP drug in women

    Lenacapavir demonstrated 100% efficacy in protecting more than 2,000 women against the infection

    - PMLiVE

    Janssen/Pharmacyclics’ ibrutinib shows continued survival benefit in chronic lymphocytic leukaemia

    The slow-growing blood cancer affects approximately 4.92 per 100,000 people every year in Europe

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links